These sort of headlines always fill me with both dread and...

These sort of headlines always fill me with both dread and excitement but invariably lead to the realisation that every biotech is on the same path. That path is towards personalised, precision medicine. Its highly unlikely that singular blockbuster drugs will lead to cures in entire cancer types. The news which Adjuster shared reveals that (beyond the headline):-.



And, this from the Mass General Cancer Centre:-

https://www.massgeneral.org/cancer-center/news/q-and-a-about-car-t-therapy-for-glioblastoma

It seems to me that Chimeric has the right approach going. Each program is working towards combination therapies within our platforms and to treat broader / more prevalent indications. So, we are investigating the synergies within our repertoire of acquired technologies.

The treatment Aust of the Year, Prof. Richard Scolyer, is undergoing is described as "A World First". It initially had me somewhat bamboozled as to how it could be described as such when there are clinical trials happening in GBM. However, his treatment is personalised, precision therapy and not performed under clinical trial conditions (more akin to how it will be the SOC one day). His treatment consisted of neoadjuvant immunotherapy followed by surgery, radiation, and ongoing combo-immunotherapy involving both cell and targeted therapy.

The Incipient drug has great promise and especially for patients with tumours in areas of the brain where tumours cannot safely be removed by surgery. Luckily, Prof Scolyer's tumour could be removed surgically without damage to his brain.

Anyway, there appears to be a lot to like about CHM's programs (each is interesting without getting too engrossed). Two assets in Ph1 A and B trials on the go and plenty of stuff going on in the lab across three assets and upteen different cancer types to keep news flowing and milestones being hit this year... 2024 is looking healthier than ever! Not too worried about what peers are achieving in the area of GBM because it is a heterogenous tumour and our CAR T program is achieving duration in an average of 4th line of treatment patients and not to mention better DCR compared to SOC.